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Introduction 
Diabetes insipidus (DI) is a disorder characterized by polydipsia, polyuria, and the formation of 
hypotonic urine. DI can be broadly classified into central DI and nephrogenic DI. In summary, 
central DI is due to the defective synthesis or release of arginine-vasopressin (AVP) or anti-
diuretic hormone (ADH) from the hypothalamo-pituitary axis. Nephrogenic DI is due to renal 
insensitivity to AVP. Transient pregnancy-associated or gestational-associated diabetes insipidus 
(GDI) is a rare condition that occurs during the third trimester affecting between 2 and 6 cases 
per 100,000 pregnancies ((1, 2, 3, 4). It is thought to occur due to elevated levels of the enzyme 
vasopressinase, which is released from the placenta and causes the degradation of ADH (5). 
During normal pregnancy the set point of the osmoregulatory system is reduced. The thirst 
threshold as well as the threshold for vasopressin release is also decreased. This leads to pregnant 
women feeling thirsty at a lower serum sodium and osmolality. The plasma sodium 
concentration typically decreases approximately 5meq/L early in pregnancy due to resetting of 
the osmoreceptors for ADH release, increased thirst, and circulatory volume dilution effects. 
This effect appears to be mediated by the increase in human chorionic gonadotropin. Another 
change is that the metabolic clearance rate of ADH markedly increases between gestational week 
10 and mid-pregnancy due to vasopressinase. The activity of vasopressinase in normal 
pregnancy has been hypothesized to retain the fluid necessary for normal pregnancy by 
increasing ADH clearance and to block uterine contractions by increasing oxytocin clearance. 
The plasma ADH concentration usually remains normal in pregnancy as the body compensates 
for the increased ADH clearance. However, some women develop transient central DI as a result 
of excessive vasopressinase where the pituitary is unable to maintain the necessary serum ADH 
level. In addition, some women may have normally reduced secretory reserve of ADH. In such 
cases, even small increases in serum vasopressinase during pregnancy could lead to gestational 
associated DI. Other studies have shown transient pregnancy-associated vasopressin-resistance 
that does not respond to either large doses of natural ADH or Desmopressin Aceteate (DDAVP) 
(6). 
Case 
A 15 year old primigravida, with no prenatal care, presented at 32 2/7 weeks of gestation with 
preterm contractions, abdominal pain and an increased BP of 154/100 mmHg. She also admitted 
to having intermittent low back pain, nausea and vomiting for the past week. She denied 
bleeding, discharge or leakage of fluid per vagina. She denied any known drug allergy and was 
not taking any medications. She had no significant medical or surgical history and denied any 
social or family history. She did not have any pertinent physical findings and was not in active 
labor. She was placed on electronic fetal monitoring and was found to have a normal, reactive 
tracing with occasional contractions. 
While in the hospital, prenatal labs were performed which were negative for Group B 
Streptococcus, negative for Gonorrhea, negative for Chlamydia, negative for Human 
Immunodeficiency Virus, negative for Hepatitis B Virus (also never been vaccinated), non-
reactive for syphilis and Rubella immune. Initial laboratory findings showed elevated serum 
sodium of 153mEq/L and it was initially believed to be the result of dehydration. After 
intravenous rehydration with normal saline, the serum sodium continued to rise and was 
160mEq/L within 24 hours. 
In addition, due to the elevated BP we also evaluated her for pregnancy induced hypertension 
(PIH) and ordered standard PIH labs. Urinalysis was negative for urine glucose, protein, 
bilirubin, ketones, hemoglobin, nitrites, and leukocytes, and had trace bacteria. Her blood counts 
were as follows: hemoglobin/hematocrit of 11.6/36.1, white blood cells 10.58, and platelets 307. 
Complete metabolic panel showed potassium 3.4, chloride 117, CO2 31, glucose 73, BUN 6, 
creatinine 0.96, calcium 8.7, total protein 6.4, albumin 3.2, total bilirubin 0.3, alkaline 
phosphatase 358, alanine aminotransferase 18, aspartate aminotransferase 26, uric acid 6.5, 
lactate dehydrogenase 243, triglycerides 87, cholesterol 203 and thyroid stimulating hormone 
1.180. Ultrasound and amniotic fluid index were normal. Fetal fibronectin was negative. DI was 
suspected and a work up was initiated. In addition, serum osmolality was also elevated. But urine 
osmolality was decreased. See Figures 1A – 1C. These laboratory findings strongly suggested DI 
associated with elevated vasopressinase. 
The DI work up to differentiate between central and nephrogenic DI was initiated with 
monitoring of serum and urine electrolytes and osmolality. The water deprivation test was not 
performed, due to concerns for the wellbeing and safety of the mother and fetus. Baseline serum 
sodium was 160mEq/L, serum osmolality was 326mOsm/kg, urine sodium was 27.0meq/L, and 
urine osmolality was 84mOsm/kg prior to a DDAVP challenge. Evaluation for central vs 
nephrogenic DI was performed by giving the patient DDAVP 2 mcg intramuscularly (IM) 
followed by checking serum and urine osmolality 2 hours later. Serum sodium of 150mEq/L and 
urine osmolality of 180mOsm/kg was seen 2 hours after the DDAVP challenge. Since the urine 
osmolality had more than doubled, a central DI was strongly suspected. 
DDAVP was held and the patient was instructed to take in oral free water to evaluate the 
patient’s ability to maintain normal serum sodium and osmolality and urine sodium and 
osmolality for 12 hours. Unfortunately, even with the patient drinking up to 3 L of free water in 
24 hours, she was not able to maintain normal electrolytes and osmolality. Her serum sodium 
and osmolality returned to abnormally high values and her urine sodium and osmolality returned 
to abnormally low levels. In fact, her urine osmolality was 39mOsm/kg. DDAVP treatment was 
immediately restarted at 2 mcg IM every 12 hours. The serum and urine electrolytes and 
osmolality were followed at 2 hours post DDAVP injection and at every 6 hours. Over the 
subsequent 24 hours, the patient’s serum and urine electrolytes and osmolality normalized. The 
dose of DDAVP was decreased to 1 mcg IM every 12 hours to prevent over correction. The 1 
mcg DDAVP dose appeared to be as effective as the 2 mcg DDAVP dose. Serum ADH level was 
also evaluated and was shown to be below detectable levels, which further supported a GDI as 
opposed to nephrogenic DI. See Figures 1A – 1C. Magnetic resonance imaging (MRI) of the 
brain did not show any pituitary mass. The fact that this patient presented in the third trimester 
and did not have any history of trauma or neurosurgery further supported a vasopressinase 
associated DI as opposed to a decreased secretory reserve of ADH or unmasking of a subclinical 
or overt DI due to the pregnant state. In these latter conditions, women usually present earlier in 
their pregnancies, when vasopressinase levels have not yet increased. We were unable to locate a 
laboratory that evaluated quantitative serum vasopressinase. However, we remain suspicious that 
this was central DI associated with excessive serum vasopressinase secretion by the placenta. 
The patient follow up was arranged at the high-risk obstetric clinic with bi-weekly basic 
metabolic panels until delivery and likely several weeks after the delivery to ensure that the 
central DI has resolved. As per patients primary care provider patient delivered healthy baby 
afterwards with resolution of DI. This further supports a vasopressinase-associated central DI. 
Conclusion 
This case demonstrated that there may be women with gestational DI that go undetected, 
especially if they have no prenatal care. Although the full impact of undiagnosed pregnancy-
associated DI is unclear, it is believed to cause an increase in morbidity and mortality for both 
the mother and fetus. In our review of the literature, we found that GDI presents in many 
different ways and it is difficult to diagnose based on symptoms alone. If a patient presents with 
elevated BP and a work up for preeclampsia reveals elevated serum sodium, a diagnosis of DI 
should be suspected. 
The treatment of choice is DDAVP intramuscular injection. Sublingual and nasal DDAVP have 
been proposed and used in the past with equal efficacy (7); IM DDAVP has been shown to be the 
treatment route in most cases described in literature as was done with our patient. The treatment 
route appeared to be determined at the discretion of the treating physician. 
Although most cases of GDI resolve upon delivery of the infant, post-partum DI several months 
after delivery had been observed requiring extension of the DDAVP treatment until the 
resolution of the DI (8). In addition, recurrence of GDI has been reported in subsequent 
pregnancies (4). We also noted that in the literature there was an association between GDI and 
multiple gestations, preeclampsia, HELLP syndrome( Hemolysis, Elevated liver enzymes, Low 
Platelets) and acute fatty liver of pregnancy due to activation of hepatic vasopressinase (2,4). 
Pathological evaluation of a placenta demonstrated no histological difference between GDI and 
normal pregnancy (8). Close post-partum follow ups will be necessary to ensure resolution of 
GDI. We have advised the patient to return to clinic for management of any future pregnancies. 
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